Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

nue opportunity; that Poly-ICR will not be useful in the treatment of GW or actinic keratosis; that we will not complete development activities or file an IND application in connection with Poly-ICR; that we will not finalize manufacturing or formulation protocols or file an IND in connection with Hsp 6/11; that we will be unable to execute our corporate restructuring as planned; that we will be unable to expand corporate development efforts as planned and that such efforts will not produce the desired results; that results from future clinical trials will not be consistent with our expectations; that we will not be able to recruit patients for our planned trials in a timely manner; our need for capital, which may not be available on a timely basis, or at all; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for obtaining clinical supply materials; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others that our planned corporate restructuring will have the anticipated affect; that we will succeed in forming strategic alliances and that such alliances will allow us to realize the greatest value for our programs; that we will commence Phase 2 clin
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
(Date:9/22/2014)... Pa. (PRWEB) September 22, 2014 ... rapid diagnostics for the food and beverage industries, ... will be distributed under a non-exclusive agreement by ... and services. , Enartis, an Esseco Group company ... to winemakers in California and other global markets ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3
... Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, ... next,generation of monoclonal antibodies based on its Dynamic ... and Chairman, will,present at the 7th Annual BIO ... Morhet,s thirty-minute presentation to potential investors and,industry partners ...
... Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), NOVATO, Calif., Oct. 28 , ... Q3 2008 ... 190.5% increase Naglazyme Net Product Revenue ... Aldurazyme Net Sales by Genzyme $38.2 ...
... ASA (OSL:DIAG),today announced that it has signed ... panEuropean provider of gene expression-based,diagnostic testing and ... marking scheduled in early2009, DiaGenic will be ... Europe its innovative blood-based,gene-expression diagnostic test for ...
Cached Biology Technology:InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests 2
(Date:9/22/2014)... In 2011 the Society of Environmental Toxicology and ... to identify and prioritize the scientific research needed to ... (PPCPs) in the environment. The effort was extended, ... of the Society,s international journal, Integrated Environmental Assessment ... accompanied by a podcast interviewing the lead author of ...
(Date:9/22/2014)... 22, 2014)The Brain & Behavior Research Foundation ... NARSAD Young Investigator Grants valued at more ... world,s most promising young scientists. Recipients of ... research will seek to identify causes, improve ... disorders that affect one in four people, ...
(Date:9/22/2014)... 22, 2014) Additive manufacturing (AM), or 3D ... production of complex-shaped metal components strong enough for ... errors and distortions, as well as quality standards ... pace with the technology. Engineers at the University ... to develop enhanced modeling and simulation (M&S) technology ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3
... 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization ... to industry, announced today that they have begun a ... for Type 2 Diabetes Mellitus.  The study is being ... daily doses of the investigational medication over periods of ...
... the University of Wisconsin-Madison have made a discovery that, ... may contribute to diseases like Alzheimer,s and Parkinson,s, which ... the brain. With proteins, shape is everything. The ... molecules about a cell, others to provide essential cellular ...
... laboratory work allowed a diverse team of University of Pittsburgh ... Nature Cell Biology that they had solved the mystery ... By discovering a mechanism by which mitochondria tiny structures ... they are damaged and need to be eliminated, the Pitt ...
Cached Biology News:Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2Zinc, proteins, and an essential cellular balancing act 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 3
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: